Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 25, 2023, reports transaction notifications for the month of August 2023. The filing details equity transactions involving Dr. Hal Barron, a Non-Executive Director, under the Company's 2017 Deferred Annual Bonus Plan and 2017 Performance Share Plan.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on specific insider transactions.
| Transaction Type | Instrument | Volume | Price (USD) | Date |
|---|---|---|---|---|
| Vesting of nil-cost option | ADSs | 36,090 | $0.00 | 2023-08-24 |
| Sale to meet tax liabilities (Option) | Ordinary Shares | 19,446 | $34.6174 | 2023-08-24 |
| Vesting of Performance Share Plan | ADSs | 107,937 | $0.00 | 2023-08-24 |
| Sale to meet tax liabilities (Performance Plan) | ADSs | 58,157 | $34.6174 | 2023-08-24 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the vesting and subsequent sale of shares by a director to satisfy tax obligations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of director share transactions.
Key Facts for Investor Verification
- Dr. Hal Barron, Non-Executive Director, vested a total of 144,027 ADSs/Ordinary Shares on August 24, 2023.
- Approximately 77,603 shares were sold on the New York Stock Exchange at $34.6174 per share to cover tax liabilities.
- The transactions relate to awards granted in 2020 under the 2017 Deferred Annual Bonus Plan and 2017 Performance Share Plan.
- No company-level financial performance data is included in this specific filing.